Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Theravance Biopharma (TBPH) Misses Q1 EPS by 33c, Revenues Beat
May 6, 2020 4:58 PM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.40), $0.33 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $19.86 million versus the consensus estimate of $18.13 million.
"As we are each challenged by COVID-19 personally and professionally, I want to thank our employees who have supported the communities we serve: the most vulnerable with respiratory illness and immune deficiencies, healthcare professionals across the globe and each other in extremely troublesome times. I could not be prouder," said Rick E Winningham, Chief Executive Officer. "Theravance Biopharma moved to remote working conditions in... More
